Novelwise Novelwise
Novelwise Novelwise
Novelwise Novelwise
  • About Novelwise
    • Company Overview & Advantages
    • The Management Team
    • Business Scope
    • Legal Consultant
    • Research & Development
    • Services
  • News
  • Pipeline
    • Metastatic Uveal Melanoma
    • Glioblastoma
    • Investigator-Initiated Trial
    • Expanded Access
  • Patients
    • Uveal Melanoma Patient Organization
    • Resources for Clinical Trial Site
  • Contact us
  • ESG
  • Services
EN
  • EN
  • 繁中
EN
  • EN
  • 繁中
Prev
Next

搜尋

  • Home
  • 首頁用資料
  • Scientific Breakthroughs

Scientific Breakthroughs

首頁用資料
  • About Novelwise
  • About Iocn
  • The US Management Teams
    • Zhong Yang Huang, Ph.D
    • Keith Chan, Ph.D
    • Tai-Sen Soong, Ph.D
  • Advantages
    • 1
    • 2
    • 3
  • Pipeline
    • Metastatic Uveal Melanoma
    • Glioblastoma
    • Investigator-Initiated Trial
  • Scientific Breakthroughs
    • Clear Market Focus
    • Innovative Pipeline
    • Strategic Collaborations

Scientific Breakthroughs

Clear Market Focus

Advancing a lead program in uveal melanoma (UM) with liver metastasis.

Innovative Pipeline

Expansion to novel HDAC8 and other selective HDAC compounds.

Strategic Collaborations

Engaging with leading CROs, academic centers, and patient advocacy groups.

Go Top
NOVELWISE
  • Tel
    1 (910) 297-9045
  • MAIL
    NWP-US-info.tw@novelwisepharma.com
  • Add
    10090 Willow Creek Road, San Diego, CA, USA
Follow
  • About Novelwise
    • Company Overview & Advantages
    • The Management Team
    • Business Scope
    • Legal Consultant
    • Research & Development
    • Services
  • Pipeline
    • Metastatic Uveal Melanoma
    • Glioblastoma
    • Investigator-Initiated Trial
    • Expanded Access
  • About Novelwise
  • Pipeline
  • News
  • Contact us
© 2026 Novelwise Pharmaceutical Corporation All rights reserved. Designed By  Winho